Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody
View Patent ↗The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above a normal level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the region treated using light). By further stimulating the immune system using an anti-CTLA-4 antibody, the systemic destruction of abnormal tissue is enhanced.
1. A method for destroying cancerous tissue within a patient's body, comprising the steps of:
(a) administering a light activated drug therapy treatment to the treatment site, the light activated drug therapy treatment destroying a portion of the cancerous tissue at the treatment site; and
(b) administering an immune system stimulating factor to the patient in association with the light activated drug therapy treatment, said immune system stimulating factor systemically enhancing destruction of cancerous tissue, even of cancerous tissue that itself has not been treated by the light activated drug therapy treatment, the immune system stimulating factor comprising an anti-CTLA-4 antibody, wherein the anti-CTLA-4 antibody is administered using a dose that is smaller than would be required to achieve a beneficial therapeutic effect without administering the light activated drug therapy treatment.
2. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered using a sub-therapeutic dose.
3. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered using the smaller dose that is selected to reduce a likelihood and/or an intensity of side effects, relative to a standard dose of the anti-CTLA-4 antibody administered in the absence of the light activated drug therapy treatment.
4. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered before administering the light activated drug therapy treatment.
5. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered after administering the light activated drug therapy treatment.
6. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered while administering the light activated drug therapy treatment.
7. The method of claim 1 , wherein an initial light activated drug therapy treatment is followed by a plurality of anti-CTLA-4 antibody treatments.
8. The method of claim 1 , wherein a plurality of light activated drug therapy treatments and a plurality of anti-CTLA-4 antibody treatments are administered.